847416-72-2

Upstream product

• 3277-89-2 phenethylmagnesium bromide 
• 847416-71-1 tert-Butyl [(cis-4-{[methoxy(methyl)amino]-carbonyl}-cyclohexyl)-methyl]carbamate 
• 103-63-9 1-phenyl-2-bromoethane 
• 619-81-8 cis-cyclohexane-1,4-dicarboxylic acid 
• 847416-69-7 butyl cis-4-{[(tert-butoxycarbonyl)amino]methyl}cyclohexanecarboxylate 
• 847416-66-4 butyl cis-4-{[(methylsulfonyl)oxy]methyl}cyclohexanecarboxylate 
• 847416-70-0 (1s,4s)-4-(((tert-butoxycarbonyl)amino)methyl)cyclohexanecarboxylic acid 
• 847416-67-5 butyl cis-4-(azidomethyl)cyclohexanecarboxylate 
• 847416-64-2 cis-4-(butoxycarbonyl)cyclohexanecarboxylic acid 
• 847416-65-3 butyl cis-4-(hydroxymethyl)cyclohexanecarboxylate 
• 847416-68-6 butyl cis-4-(aminomethyl)cyclohexanecarboxylate 

Downstream Products

• 847416-73-3 (+/-)-tert-butyl {[cis-4-(1-hydroxy-3-phenylpropyl)cyclohexyl]methyl}carbamate 

Relevant academic research and scientific papers

4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS

Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.